# A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

> **NCT01897519** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 56 (actual)

## Conditions studied

- Cardiothoracic Surgery
- Vascular Surgery

## Interventions

- **DRUG:** Placebo
- **DRUG:** ABT-719

## Key facts

- **NCT ID:** NCT01897519
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Topline results from study M13-796 showed an overall lack of efficacy. There were no safety concerns.
- **Last updated:** 2014-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897519, "A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01897519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*